Effect of a new calcium antagonist on hemodynamics at rest and exercise loading in patients with essential hypertension

S. Suzuki, T. Hashimoto, S. Kusano, Kakota Gaston Kapuku, T. Utsunomiya, K. Yano

Research output: Contribution to journalArticle

2 Scopus citations


MPC-1304 ((±)-methyl 2-oxopropyl 1,4-dihydro 2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate, CAS 86780-90-7), a new calcium antagonist, was orally administered to 10 outpatients with mild essential hypertension. It was observed that MPC-1304 inhibited elevations of blood pressure both at rest and under exercise loading without any adverse hemodynamie effects. The findings obtained indicated that MPC-1304 would be clinically useful in the treatment of hypertensive patients undergoing therapy while continuing normal everyday activities including physical exertion.

Original languageEnglish (US)
Pages (from-to)1152-1156
Number of pages5
JournalArzneimittel-Forschung/Drug Research
Issue number11
Publication statusPublished - Jan 1 1993



  • (±)-methyl 2-oxopropyl 1,4-dihydro 2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine dicarboxylate
  • CAS 86780-90-7
  • MPC-1304
  • antihypertensives
  • hypertension, essential

ASJC Scopus subject areas

  • Drug Discovery

Cite this